Studies have reported that silence of linc00210 by ASO effectively repressed the proliferation and invasion of HCC and downregulation of lncRNA CASC9 via RNAi dramatically decreased the tumor formation [96, 97] By now, mature and commercial experiences of these techniques in HBV application [98, 99] could provide solid basis for therapy of lncRNAs in HCC. The gene discussed is CASC9; the disease is hepatocellular carcinoma.